Last $5.24 USD
Change Today -0.04 / -0.76%
Volume 56.1K
HBIO On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

harvard bioscience inc (HBIO) Snapshot

Open
$5.23
Previous Close
$5.28
Day High
$5.25
Day Low
$5.18
52 Week High
12/31/14 - $5.93
52 Week Low
06/25/14 - $3.68
Market Cap
169.9M
Average Volume 10 Days
92.1K
EPS TTM
$0.16
Shares Outstanding
32.4M
EX-Date
--
P/E TM
33.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for HARVARD BIOSCIENCE INC (HBIO)

Related News

No related news articles were found.

harvard bioscience inc (HBIO) Related Businessweek News

No Related Businessweek News Found

harvard bioscience inc (HBIO) Details

Harvard Bioscience, Inc. develops, manufactures, distributes, and markets scientific instruments, systems, and lab consumables used in life science research. The company offers syringe pumps and peristaltic pumps primarily under the Harvard Apparatus and KD Scientific brands, as well as component pumping modules; and lab equipment and supplies comprising pipettes and pipette tips, gloves, gel electrophoresis and autoradiography products, thermal cycler accessories and reagents, general lab equipment and consumables, and tissue culture products primarily under the Denville Scientific, Hoefer, and Scie-Plas brands. It also provides molecular analysis products, such as spectrophotometers under the UltroSpec, NovaSpec, Libra, and BioDrop brands; microplate readers under the Asys Hitech and Anthos Labtec brands; and amino acid analyzers under the Biochrom brand. In addition, the company offers electroporation and electrofusion products comprising systems and generators, electrodes, and accessories under the Harvard Apparatus BTX brand; and cell electrophysiology products, such as equipment for patch clamps, amplifiers, bilayer workstations, temperature controllers, chambers, and accessories under the Warner Instrument brand. Further, it provides physiology products, which include a range of instruments and accessories for tissue, organ, and animal based lab research, ranging from surgical products, infusion systems, microdialysis instruments, behavior research products, isolated perfused organ and tissue bath systems, and research-based regenerative medicine products under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, and InBreath Bioreactor brands. It markets its products to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies through catalogs, distributors, direct sales force, and its Websites. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

345 Employees
Last Reported Date: 03/14/14
Founded in 1901

harvard bioscience inc (HBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $271.8K
Co-Founder and Director
Total Annual Compensation: $420.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $54.8K
Vice President of Strategic Marketing and Bus...
Total Annual Compensation: $64.5K
Vice President of Global Sales
Total Annual Compensation: $34.0K
Compensation as of Fiscal Year 2013.

harvard bioscience inc (HBIO) Key Developments

Harvard Bioscience Inc. Presents at Equities.com Small-Cap Stars Conference, Dec-18-2014 02:50 PM

Harvard Bioscience Inc. Presents at Equities.com Small-Cap Stars Conference, Dec-18-2014 02:50 PM. Venue: NASDAQ MarketSite, New York, New York, United States.

Harvard Bioscience Appoints Bertrand Loy to Board of Directors

Harvard Bioscience Inc. has appointed Bertrand Loy to its Board of Directors, effective immediately. Mr. Loy is President and CEO of Entegris Inc. He earlier served as Chief Operating Officer and Chief Administrative Officer of Entegris.

Harvard Bioscience Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

Harvard Bioscience Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. Revenues for the three months ended September 30, 2014 were $25.4 million, an increase of approximately $0.3 million, or 1.2% compared to revenues of $25.1 million for the three months ended September 30, 2013. The increase in Revenue was the result of currency translation, due to a weaker U.S. dollar compared to the British pound sterling. Income from continuing operations, as measured under U.S. generally accepted accounting principles ("GAAP"), was $0.6 million, or $0.02 per diluted share, for the three months ended September 30, 2014 compared to a loss of $48,000, or $0.00 per diluted share, for the same quarter in 2013. Overall, the favorable year-to-year quarterly GAAP earnings comparison was due primarily to transaction costs incurred during the three months ended September 30, 2013, as well as lower general and administrative expenses quarter over quarter. Income from continuing operations, on a non-GAAP basis, increased 46% to $1.9 million for the third quarter 2014, and increased 50% to $0.06 per diluted share, compared to $1.3 million, or $0.04 per diluted share, for the three months ended September 30, 2013. Operating income was $1.425 million against $0.414 million a year ago. Net income was $0.633 million or $0.02 diluted per share against net loss of $0.983 million or $0.03 diluted per share a year ago. Non-GAAP adjusted operating income was $2.92 million against $2.11 million a year ago. Non-GAAP adjusted income from continuing operations was $1.93 million against $1.32 million a year ago. Non-GAAP adjusted diluted earnings per common share from continuing operations was $0.06 against $0.04 a year ago. Revenues for the nine months ended September 30, 2014 were $78.3 million, an increase of approximately $1.0 million, or 1.3% compared to revenues of $77.3 million for the nine months ended September 30, 2013. Income from continuing operations, as measured under GAAP, was $2.4 million, or $0.07 per diluted share, for the nine months ended September 30, 2014 compared to $1.0 million, or $0.03 per diluted share, for the same period in 2013. Overall, the favorable year-to-year GAAP earnings comparison was due primarily to transaction costs incurred during the nine months ended September 30, 2013, partially offset by higher research and development expenses. Income from continuing operations, on a non-GAAP basis, was $5.5 million, or $0.17 per diluted share, for the nine months ended September 30, 2014 compared to $5.4 million, or $0.17 per diluted share, for the same period in 2013. Operating income was $4.49 million against $2.48 million a year ago. Net income was $2.37 million or $0.07 diluted per share against net loss of $1.07 million or $0.04 diluted per share a year ago. Net cash provided by operating activities was $3.088 million against $2.811 million a year ago. Non-GAAP adjusted operating income was $8.56 million against $8.23 million a year ago. Non-GAAP adjusted income from continuing operations was $5.54 million against $5.39 million a year ago. Non-GAAP adjusted diluted earnings per common share from continuing operations was $0.17 against $0.17 a year ago. Capital expenditures were $1.2 million for the nine months ended September 30, 2014, compared to $1.1 million for the same period last year. The increase in capital expenditures year-to-date compared to last year was due to timing of normal capital spending on maintenance capital. The company is increasing its financial guidance from February 27, 2014 to reflect its acquisitions of Multi Channel Systems MCS and Triangle BioSystems. The company now expects revenues to be approximately $107-$108 million, or an approximately 2% to 3% increase compared to 2013's revenues. The company expects to report full-year 2014 non-GAAP diluted earnings per share of $0.26 to $0.27, an approximately 20% to 22% increase compared with 2013's non-GAAP diluted earnings per share. This translates to GAAP diluted earnings per share of approximately $0.14 to $0.15. The company continues to forecast effective tax rate in the range of 28% to 30%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBIO:US $5.24 USD -0.04

HBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $140.31 USD -0.51
Bio-Rad Laboratories Inc $114.82 USD +1.05
Danaher Corp $83.93 USD +1.08
PerkinElmer Inc $44.86 USD +0.37
Thermo Fisher Scientific Inc $127.96 USD +3.62
View Industry Companies
 

Industry Analysis

HBIO

Industry Average

Valuation HBIO Industry Range
Price/Earnings 82.0x
Price/Sales 1.6x
Price/Book 1.8x
Price/Cash Flow 41.8x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARVARD BIOSCIENCE INC, please visit www.harvardbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.